Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials
Neoadjuvant therapy may improve survival compared with upfront surgery in patients with resectable and borderline resectable pancreatic cancer, but high-quality evidence is lacking.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Jacob L. van Dam, Quisette P. Janssen, Marc G. Besselink, Marjolein Y.V. Homs, Hjalmar C. van Santvoort, Geertjan van Tienhoven, Roeland F. de Wilde, Johanna W. Wilmink, Casper H.J. van Eijck, Bas Groot Koerkamp, Dutch Pancreatic Cancer Group Tags: Original Research Source Type: research
More News: Cancer | Cancer & Oncology | Neoadjuvant Therapy | Netherlands Health | Pancreas | Pancreatic Cancer